ArticleJCO precision oncology2024
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer.
Article in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 4 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Circulating Tumor DNA and Circulating Tumor Cells in Liquid Biopsy as Post-Treatment Prognostic Biomarkers in Early Breast Cancer: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2026Pooled it
- Accuracy of ctDNA-based minimal residual disease detection in predicting postoperative recurrence of breast cancer: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis.Breast cancer research : BCR · 2025Pooled it
- Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Recurrence in Real Time: Rethinking Breast Cancer Follow-Up Evaluation with Circulating Tumor DNA.Annals of surgical oncology · 2026Article
- Perioperative ctDNA as a prognostic biomarker in endometrial cancer - the CODEC study.Translational oncology · 2026Article
- Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.JCO precision oncology · 2026Article
- Common analysis pitfalls in longitudinal ctDNA studies: lead time, sensitivity and immortal time bias.EBioMedicine · 2026Review
- MammaTrace - a tumor naïve cell-free DNA methylation test for minimal residual disease in breast cancer.NPJ precision oncology · 2026Article
- Circulating Tumor DNA Analysis in Adrenocortical Carcinoma: A Retrospective Cohort Study.Endocrine pathology · 2026Article
- Review
- Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast Cancer.medRxiv : the preprint server for health sciences · 2026Article
- Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-Breast.Future oncology (London, England) · 2026Observational
- Article
- Biological basis and clinical translation prospects of circulating cell-free DNA in precision management of breast cancer (Review).Oncology letters · 2026Review
- Dual ctDNA and CTCs analysis for minimal residual disease detection and relapse monitoring in early-stage breast cancer.NPJ breast cancer · 2026Article
- Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial.NPJ breast cancer · 2026Article
- Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer.Molecular oncology · 2026Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
31 authors at 8 institutions in 4 countries.
Funding
Abstract
purposeHere, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer.
methodsA total of 156 patients with primary breast cancer were monitored clinically for up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples were prospectively collected, and analyzed retrospectively to detect residual disease by ultradeep sequencing using ctDNA assays, developed from primary tumor whole-exome sequencing data.
resultsPersonalized Signatera assays detected ctDNA ahead of clinical or radiologic relapse in 30 of the 34 patients who relapsed (patient-level sensitivity of 88.2%). Relapse was predicted with a lead interval of up to 38 months (median, 10.5 months; range, 0-38 months), and ctDNA positivity was associated with shorter relapse-free survival (
conclusionSerial postoperative ctDNA assessment has strong prognostic value, provides a potential window for earlier therapeutic intervention, and may enable more effective monitoring than current clinical tests such as cancer antigen 15-3. Our study provides evidence that those with serially negative ctDNA tests have superior clinical outcomes, providing reassurance to patients with breast cancer. For select cases with HR+ disease, decisions about treatment management might require serial monitoring despite the ctDNA-positive result.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.